Compare JSPR & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JSPR | BNGO |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.9M |
| IPO Year | N/A | 2018 |
| Metric | JSPR | BNGO |
|---|---|---|
| Price | $0.69 | $1.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $15.50 | $7.00 |
| AVG Volume (30 Days) | ★ 2.3M | 116.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.32 | $1.06 |
| 52 Week High | $3.25 | $5.50 |
| Indicator | JSPR | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 40.82 |
| Support Level | $0.62 | $1.08 |
| Resistance Level | $1.05 | $1.19 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 43.37 | 0.98 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.